Peter Stenvinkel

Prof. Peter Stenvinkel

Real Medicine, Karolinska Institutet, Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Kidney International
Verified
Journal Article
Open access
PDF file
DFDenis Fouque
Denis Fouque
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
JKJ. Kopple
J. Kopple
NCN. Cano
N. Cano
PCP. Chauveau
P. Chauveau
CWC. Wanner
C. Wanner
The recent research findings concerning syndromes of muscle wasting, malnutrition, and inflammation in individuals with chronic kidney disease (CKD) or acute kidney injury (AKI) have led to a need for new terminology. To address this need, the International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI. The ISRNM expert panel recommends the term ‘protein–energy wasting’ for loss of body protein mass and fuel reserves. ‘Kidney disease wasting’ refers to the occurrence of protein–energy wasting in CKD or AKI regardless of the cause. Cachexia is a severe form of protein–energy wasting that occurs infrequently in kidney disease. Protein–energy wasting is diagnosed if three characteristics are present (low serum levels of albumin, transthyretin, or cholesterol), reduced body mass (low or reduced body or fat mass or weight loss with reduced intake of protein and energy), and reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm muscle circumference). The kidney disease wasting is divided into two main categories of CKD- and AKI-associated protein–energy wasting. Measures of chronic inflammation or other developing tests can be useful clues for the existence of protein–energy wasting but do not define protein–energy wasting. Clinical staging and potential treatment strategies for protein–energy wasting are to be developed in the future.

1 May 2003 in Kidney International
Verified
Journal Article
Closed access
RVRaymond Vanholder
Raymond Vanholder
F(For the European Uremic Toxin Work Group (EUTox)
For the European Uremic Toxin Work Group (EUTox)
RSRita De Smet
Rita De Smet
GGGriet Glorieux
Griet Glorieux
AAAngel Argilés
Angel Argilés
WZWalter Zidek
Walter Zidek

1 May 1999 in Kidney International
Verified
Journal Article
Open access
PSPeter Stenvinkel
Peter Stenvinkel
OHOlof Heimbürger
Olof Heimbürger
FPFurcy Paultre
Furcy Paultre
UDUlf Diczfalusy
Ulf Diczfalusy
TWTao Wang
Tao Wang
TJTomas Jogestrand
Tomas Jogestrand
Atherosclerotic cardiovascular disease and malnutrition are widely recognized as leading causes of the increased morbidity and mortality observed in uremic patients. C-reactive protein (CRP), an acute-phase protein, is a predictor of cardiovascular mortality in nonrenal patient populations. In chronic renal failure (CRF), the prevalence of an acute-phase response has been associated with an increased mortality. One hundred and nine predialysis patients (age 52 +/- 1 years) with terminal CRF (glomerular filtration rate 7 +/- 1 ml/min) were studied. By using noninvasive B-mode ultrasonography, the cross-sectional carotid intima-media area was calculated, and the presence or absence of carotid plaques was determined. Nutritional status was assessed by subjective global assessment (SGA), dual-energy x-ray absorptiometry (DXA), serum albumin, serum creatinine, serum urea, and 24-hour urine urea excretion. The presence of an inflammatory reaction was assessed by CRP, fibrinogen (N = 46), and tumor necrosis factor-alpha (TNF-alpha; N = 87). Lipid parameters, including Lp(a) and apo(a)-isoforms, as well as markers of oxidative stress (autoantibodies against oxidized low-density lipoprotein and vitamin E), were also determined. Compared with healthy controls, CRF patients had an increased mean carotid intima-media area (18.3 +/- 0.6 vs. 13.2 +/- 0.7 mm2, P < 0.0001) and a higher prevalence of carotid plaques (72 vs. 32%, P = 0.001). The prevalence of malnutrition (SGA 2 to 4) was 44%, and 32% of all patients had an acute-phase response (CRP > or = 10 mg/liter). Malnourished patients had higher CRP levels (23 +/- 3 vs. 13 +/- 2 mg/liter, P < 0.01), elevated calculated intima-media area (20.2 +/- 0.8 vs. 16.9 +/- 0.7 mm2, P < 0.01) and a higher prevalence of carotid plaques (90 vs. 60%, P < 0.0001) compared with well-nourished patients. During stepwise multivariate analysis adjusting for age and gender, vitamin E (P < 0.05) and CRP (P < 0.05) remained associated with an increased intima-media area. The presence of carotid plaques was significantly associated with age (P < 0.001), log oxidized low-density lipoprotein (oxLDL; P < 0.01), and small apo(a) isoform size (P < 0.05) in a multivariate logistic regression model. These results indicate that the rapidly developing atherosclerosis in advanced CRF appears to be caused by a synergism of different mechanisms, such as malnutrition, inflammation, oxidative stress, and genetic components. Apart from classic risk factors, low vitamin E levels and elevated CRP levels are associated with an increased intima-media area, whereas small molecular weight apo(a) isoforms and increased levels of oxLDL are associated with the presence of carotid plaques.

1 November 2002 in Kidney International
Verified
Journal Article
Closed access
JHJonathan Himmelfarb
Jonathan Himmelfarb
PSPeter Stenvinkel
Peter Stenvinkel
TITalat Alp Ikizler
Talat Alp Ikizler
RHRaymond M. Hakim
Raymond M. Hakim

1 September 2008 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
SKSawako Kato
Sawako Kato
MCMichal Chmielewski
Michal Chmielewski
HHHirokazu Honda
Hirokazu Honda
RPRoberto Pécoits-Filho
Roberto Pécoits-Filho
SMSeiichi Matsuo
Seiichi Matsuo
BLBengt Lindholm
Bengt Lindholm
End-stage renal disease (ESRD) is associated with significantly increased morbidity and mortality resulting from cardiovascular disease (CVD) and infections, accounting for 50% and 20%, respectively, of the total mortality in ESRD patients. It is possible that these two complications are linked to alterations in the immune system in ESRD, as uremia is associated with a state of immune dysfunction characterized by immunodepression that contributes to the high prevalence of infections among these patients, as well as by immunoactivation resulting in inflammation that may contribute to CVD. This review describes disorders of the innate and adaptive immune systems in ESRD, underlining the specific role of ESRD-associated disturbances of Toll-like receptors. Finally, based on the emerging links between the alterations of immune system, CVD, and infections in ESRD patients, it emphasizes the potential role of the immune dysfunction in ESRD as an underlying cause for the high mortality in this patient population and the need for more studies in this area.

1 October 2017 in The Lancet
Verified
Journal Article
Closed access
ALAdeera Levin
Adeera Levin
MTMarcello Tonelli
Marcello Tonelli
JBJoseph Bonventre
Joseph Bonventre
JCJosef Coresh
Josef Coresh
JDJo-Ann Donner
Jo-Ann Donner
CYChih-Wei Yang
Chih-Wei Yang